The Avanzar study could read out shortly.
ApexOnco Front Page
Recent articles
Satri-cel is filed for gastric cancer approval in China.
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
Starglo isn't applicable to a US population, an adcom rules.
PF-08046037 joins PF-08046054 in clinical development.
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
RPCAR01 starts a phase 1 study, albeit one sponsored by academics.
